Polaryx Therapeutics, Inc.
PLYX · XNASCIK 2075320fmd_0CH0YJTXA5XC0CJMGT41SCAQ3YManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2024 to Sep 30, 2026, 8 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Research and development | 3 | 6 |
| Total operating expenses | 4 | 8 |
| Operating income | (4) | (8) |
| Income before taxes | (30) | (9) |
| Net income | (30) | (9) |